Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
H. Lee Moffitt Cancer Center and Research Institute
Headquarters: Tampa, FL, United States of America
Website: http://www.moffitt.org
Year Founded: 1986
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 13, 2025
Management Tracks
Scarlett steps down as CEO of Geron
Plus: Purespring names Haseeb Ahmad CEO, and updates from Cellevate and Moffitt Cancer Center
BioCentury | Dec 19, 2024
Product Development
Tertiary lymphoid structures: Key to predicting and improving cancer immunotherapy response?
At least two companies are preparing to take inducers of tertiary lymphoid structure into the clinic
BioCentury | Oct 18, 2024
Management Tracks
Hoess succeeds Crawford at ViaNautis
Plus: Korenberg now CFO of Palvella and updates from Moffitt and CHMP
BioCentury | Nov 3, 2023
Discovery & Translation
Dimeric IgA targets intracellular oncogenes; plus taRNAs and more
BioCentury’s roundup of translational innovations
BioCentury | Aug 27, 2019
Company News
Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano
BioCentury | Aug 15, 2019
Company News
Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks
BioCentury | May 31, 2019
Targets & Mechanisms
Targeting cancer evolution offers a way to foil drug resistance
Solutions to cancer drug resistance could come from new understanding about tumor evolution and advances in liquid biopsies.
BioCentury | May 29, 2019
Company News
May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more
Items per page:
1 - 10 of 47